Immunic to Participate in Key November Conferences

Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focusing on oral therapies for chronic inflammatory and autoimmune diseases, has confirmed its participation in two significant conferences in November. The company aims to engage in partnering activities at BIO-Europe between November 3-5, in Vienna, Austria. CEO Daniel Vitt, Ph.D., along with Chief Scientific Officer Hella Kohlhof, Ph.D., and VP of Investor Relations Jessica Breu will represent Immunic.

Additionally, Dr. Vitt and President Jason Tardio will host individual meetings during the Jefferies Global Healthcare Conference in London on November 19-20. These events provide an opportunity for Immunic to engage with industry peers and investors, aiming to enhance visibility and partnerships within the biotech community.